corcept.png
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
26 juil. 2023 16h05 HE | Corcept Therapeutics Incorporated
MENLO PARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update...
corcept.png
Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
17 juil. 2023 16h05 HE | Corcept Therapeutics Incorporated
Phase 1b study demonstrates that miricorilant, a selective cortisol modulator, effectively reduces liver fat, improves liver health and key metabolic and lipid measures and is well-toleratedCorcept...
corcept.png
Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer
27 juin 2023 08h00 HE | Corcept Therapeutics Incorporated
Relacorilant plus nab-paclitaxel improved progression-free survival (PFS), duration of response (DoR) and overall survival (OS), without increasing side effects, compared to nab-paclitaxel...
corcept.png
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
03 mai 2023 16h05 HE | Corcept Therapeutics Incorporated
MENLO PARK, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
corcept.png
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
26 avr. 2023 16h05 HE | Corcept Therapeutics Incorporated
MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update...
corcept.png
Corcept Therapeutics Announces Final Results of Tender Offer
05 avr. 2023 16h05 HE | Corcept Therapeutics Incorporated
MENLO PARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
corcept.png
Corcept Therapeutics Announces Preliminary Results of Tender Offer
03 avr. 2023 08h00 HE | Corcept Therapeutics Incorporated
MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
corcept.png
Corcept Therapeutics Initiates CATALYST Clinical Trial
28 mars 2023 16h05 HE | Corcept Therapeutics Incorporated
MENLO PARK, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...
corcept.png
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock
06 mars 2023 08h00 HE | Corcept Therapeutics Incorporated
MENLO PARK, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of...
corcept.png
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update
28 févr. 2023 16h05 HE | Corcept Therapeutics Incorporated
MENLO PARK, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat...